Pharmaceutical giant Eli Lilly is about to face some fierce competition -- from itself. The company just announced plans to offer a generic version of its own insulin drug, Humalog, at half price. The move comes just weeks after another big drug company, Amgen, release an identical version of its novel high-cholesterol treatment, Repatha, with a different code than the version currently on the market.
What gives?
